drugset

drugset / Trial / NCT06091956

A Study of Deucravacitinib to Treat LPP and FFA

NCT06091956 ↗

Phase 2 Completed 12 enrolled Mayo Clinic Bristol-Myers Squibb · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this clinical research study is to learn more about the use of Deucravacitinib in the treatment of Lichen Planopilaris.

Timeline

Start: 2023-11-07
Primary completion: 2024-05-21
Completion: 2024-12-24

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CRAVACITINIB	Small molecule	6 mg	Oral

Indications